Skip to main content
Clinical Trials/ISRCTN88729946
ISRCTN88729946
Completed
Not Applicable

Treatment of acute hepatitis C infection: immediate therapy of all patients with peg-interferon alpha-2b alone versus delayed therapy of patients not eliminating hepatitis C virus (HCV) spontaneously with peg-interferon alpha-2b plus ribaviri

Hannover Medical School (Medizinische Hochschule Hannover) (Germany)0 sites135 target enrollmentSeptember 9, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute hepatitis C
Sponsor
Hannover Medical School (Medizinische Hochschule Hannover) (Germany)
Enrollment
135
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 9, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hannover Medical School (Medizinische Hochschule Hannover) (Germany)

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with acute HCV infection and detectable HCV RNA
  • 2\. More than 18 years
  • 3\. Compensated liver disease
  • 4\. Negative urine or blood pregnancy test
  • 5\. Willingness to give written informed consent

Exclusion Criteria

  • 1\. Other possible reasons for acute HCV infection
  • 2\. Liver cirrhosis
  • 3\. Pregnancy or breast feeding
  • 4\. Previous antiviral therapy with interferon or ribavirin
  • 5\. Positive test results for anti hepatitis A virus (HAV) IgM antib., HBsAg, anti\-HBc IgM antib., HBeAg, anti human immunodeficiency virus (HIV)
  • 6\. History or evidence for chronic liver disease
  • 7\. History of severe psychiatric disease, thyroid dysfunction poorly controlled
  • 8\. History or evidence for severe illness
  • 9\. Drug use within 6 mionths prior to first dose of study drug

Outcomes

Primary Outcomes

Not specified

Similar Trials